Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie’s disease: A prospective randomized clinical trial

Figures & data

Figure 1. CONSORT flowchart of the enrolled patients.

Table 1. Baseline characterestics of the studied groups.

	Group A (n = 21)	Group B (n = 21)	P value
Age (years)	51.3 ± 5.94	52.8 ± 7.23	0.488
BMI (Kg/m^2)	24.7 ± 1.68	23.95 ± 2.04	0.193
Duration of the disease	3.2 ± 1.1	2.7 ± 1.02	0.138
DM	13 (61.9%)	11 (52.38%)	0.755
Cardiovascular disease	7 (33.33%)	6 (28.57%)	0.738

Data displayed as mean ± SD or frequency (%), BMI: body mass index, DM: diabetes mellitus.

Table 2. Clinical data of the studied groups.

		Group A (n = 21)	Group B (n = 21)	P value
Plaque position	Proximal	6 (28.57%)	5 (23.81%)	0.289
	Medium	2 (9.52%)	6 (28.57%)
	Distal	13 (61.9%)	10 (47.62%)
Curvature side	Dorsal	11 (52.38%)	14 (66.67%)	0.560
	Right lateral	5 (23.81%)	3 (14.29%)
	Left lateral	2 (9.52%)	3 (14.29%)
	Right lateral-dorsal	3 (14.29%)	1 (4.76%)

Data presented as frequency (%).

Table 3. Plaque size and penile curvature of the studied groups.

		Group A (n = 21)	Group B (n = 21)	P value
Plaque size (mm)	Baseline	10.2 ± 2.32	9.9 ± 2.14	0.631
	12 weeks after therapy	7.7 ± 2.33	9.3 ± 2.37	0.031*
	P value within group	<0.001*	0.234	—
Penile curvature	Baseline	34.1 ± 6.77	36.2 ± 7.43	0.335
	12 weeks after therapy	24.7 ± 9.72	30.8 ± 8.63	0.038*
	P value within group	0.005*	0.047*	—

Data displayed as mean ± SD, *: statistically significant as p value < 0.05.